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Abstract 
Understanding the structure, functionalities and biology of functional amyloids is an 
issue of emerging interest. Inclusion bodies, namely protein clusters formed in 
recombinant bacteria during protein production processes, have emerged as 
unanticipated, highly tunable models for the scrutiny of the physiology and 
architecture of functional amyloids. Based on an amyloidal skeleton combined with 
varying amounts of native or native-like protein forms, bacterial inclusion bodies 
exhibit an unusual arrangement that confers mechanical stability, biological activity 
and conditional protein release, being thus exploitable as versatile biomaterials. The 
applicability of inclusion bodies in biotechnology as enriched sources of protein and 
reusable catalysts, and in biomedicine as biocompatible topographies, nanopills, or 
mimetics of endocrine secretory granules has been largely validated. Beyond these 
uses, the dissection of how recombinant bacteria manage the aggregation of 
functional protein species into structures of highly variable complexity offers insights 
about unsuspected connections between protein quality (conformational status 
compatible with functionality) and cell physiology.  
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1. Introduction   
Many bacterial species, as transformers of organic and inorganic substances, are used 
in food technologies and other fields with established or rising economic impact such 
as fabrics, bioremediation or mining, for performing controlled processes of industrial 
interest (Demain, 2000). This is done by exploiting the metabolic diversity and 
versatility of prokaryotic cells that, due to their evolutionary adaptation to different 
environments and physicochemical conditions, developed a vast spectrum of 
alternative physiologic strategies. In addition, bacteria have been also engineered as 
cell factories for the production of macromolecules (mainly proteins, nucleic acids and 
polymers), metal particles and secondary metabolites. The production of these 
substances is continuously optimized by process (tailored culture conditions for fast 
grow or high productivity) and genetic approaches (mutant strains with improved 
functionalities and metabolic routes). The resulting spectrum of biological products 
infiltrates diverse areas in biotechnology and pharmaceutical industries. Furthermore, 
an increasing number of applications emerges also in very diverse fields such as 
energy, electronics, material sciences and nanotechnologies (Rodriguez-Carmona & 
Villaverde, 2010, Du, et al., 2011, Lee, et al., 2012, Malik, et al., 2018). 
Among bacterial products, proteins are of special interest as structural but also 
functional agents, and they can be easily produced by conventional recombinant DNA 
strategies or by gene synthesis (Hartley, 2006). Proteins are produced not only in 
bacteria (Ferrer-Miralles & Villaverde, 2013, Overton, 2014) but also in other cell 
factories (mainly yeasts, filamentous fungi, mammalian and insect cells, and whole 
plant or animals) (Corchero, et al., 2013). Recombinant enzymes are employed in food 
technologies, in chemicals, detergent and fabric manufacture, as well as 
biopharmaceuticals for protein replacement therapies and in life sciences research 
(Vellard, 2003). In this context, hormones, enzymes, antigens and antibodies are 
common protein drugs and a significant number of them, approved and marketed for 
human therapies, are produced in bacterial cells (Ferrer-Miralles, et al., 2009, Overton, 
2014, Sanchez-Garcia, et al., 2016). Many vaccines are based on conventional 
recombinant proteins (Nascimento & Leite, 2012) or on a specific category of self-
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assembling protein materials named virus-like particles (Pattenden, et al., 2005, Lua, et 
al., 2014), that mimic structural and antigenic features of natural viruses.  
Protein production in bacterial cell factories was indeed made possible through the 
development of recombinant DNA technologies (Ferrer-Miralles, et al., 2009), that 
raised in the late 70’s with the discovery and application of restriction enzymes. Since 
then, recombinant protein production has become a routine practice worldwide. 
Protein production is reached by exploiting an expanding catalogue of bacterial species 
as biological factories. These show distinguishable properties regarding culture 
requirements, use of carbon sources, metabolic capabilities and protein secretability 
(Corchero, et al., 2013, Ferrer-Miralles & Villaverde, 2013). The enterobacterium 
Escherichia coli was the initial recombinant cell factory and still the most universally 
preferred system for protein production, because of its easy and fast culture, deep 
understanding of genetics and physiology as well as for the availability of numerous 
tools for genetic manipulation (Rosano & Ceccarelli, 2014).  
The vast majority of proteins in nature are active as soluble species. Then, protein 
production processes are aimed to obtain soluble proteins with native, functional 
structure to nicely mimic their natural activities. While the native conformation  is 
reached through a  correct folding process,-protein misfolding and consequent 
aggregation in the cytosol (for intracellular) or the periplasm (for secreted) is a very 
common event. As a consequence, in most production processes the occurrence of 
insoluble protein species has been reported, often accompanied by a fraction of 
soluble protein (de Marco, 2013). The ratio between soluble fraction and total protein 
(the supposed percentage of soluble and functionally folded protein) is then commonly 
used as an indication for a successful process.  
 
2. Inclusion bodies in recombinant bacteria 
Aggregates of recombinant proteins occur as small supramolecular entities in the 
soluble cell fraction or as larger protein clusters that precipitate as insoluble materials. 
Therefore, the recombinant protein species range along a spectrum of conformational 
versions that embrace soluble protein species, soluble aggregates and insoluble 
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aggregates (Schrodel & de Marco, 2005, Martinez-Alonso, et al., 2008). Soluble 
aggregates or proto-aggregates have been usually considered as precursors of large 
protein deposits (Martinez-Alonso, et al., 2009). Aggregated proteins tend to 
eventually accumulate in recombinant cells as refractile (under optical microscope 
visualization), electrodense (under transmission electron microscope visualization) 
submicron particles known as inclusion bodies (IBs, Figure 1A, B) (Villaverde & Carrio, 
2003). IBs have been considered to be a main bottleneck in the protein production 
processes and their formation has been associated to improper protein folding or 
misfolding (Villaverde & Carrio, 2003, Baneyx & Mujacic, 2004). Despite the 
development of diverse approaches and algorithms to predict protein solubility based 
on the primary sequence (Smialowski, et al., 2007, Tjong & Zhou, 2008, Magnan, et al., 
2009, Diaz, et al., 2010, Agostini, et al., 2012, de Groot, et al., 2012, Huang, et al., 
2012, Smialowski, et al., 2012, Chang, et al., 2014, Yang, et al., 2016, Paladin, et al., 
2017, Roche, et al., 2017, Khurana, et al., 2018, Rawi, et al., 2018), the tendency of a 
given recombinant polypeptide to form IBs cannot be accurately anticipated. While the 
progress in in silico prediction of solubility would be highly convenient (as it might 
allow preventing unsuccessful efforts in the production of insoluble proteins and then 
save costs) it is still an unmet target. This is likely because solubility of a recombinant 
protein does not merely lie on the amino acid sequence, but also on multifactorial and 
highly dynamic physiological issues, such as cell energetics, the availability of 
molecular chaperones, foldases, stabilizing osmolytes, the folding and secretion 
kinetics, or the effect of incorrect post-translational modifications (Bandyopadhyay, et 
al., 2012). The formation of IBs is then an important obstacle in protein production 
processes, as their occurrence undermine the relative accumulation of soluble protein 
species versus the aggregated versions, that is, it reduces the solubility of the target 
protein.  
In addition, protein aggregation has been historically associated to lack of 
functionality, because reaching the native protein conformation is generally linked to 
solubility (Baneyx & Mujacic, 2004). The generic tendency to aggregation and 
insolubility of recombinant proteins has then pushed to develop strategies for protein 
production addressed to minimize IB formation, which has been only moderately 
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successful and strongly protein-dependent (Sorensen & Mortensen, 2005, Sorensen & 
Mortensen, 2005). Being mechanically stable (Vogel, et al., 2002, Garcia-Fruitos, et al., 
2009), IBs can be purified from bacterial cells upon cell breaking and mild-to-harsh 
rinsing treatments or density gradient centrifugation (Schrodel & de Marco, 2005, 
Rodriguez-Carmona, et al., 2010, Seras-Franzoso, et al., 2015). This offers a particulate 
material usable as relatively pure source of recombinant protein. In this context, when 
attempts to prevent IB formation failed, IBs have been exploited in protein 
biotechnology as relatively pure source of proteins (Gatti-Lafranconi, et al., 2011) to be 
recovered in vitro. This approach considers first the disintegration of IBs by the 
application of more or less aggressive chaotropic agents or detergents and a successive 
protein refolding process under controlled conditions. These approaches have been 
developed in parallel to the advances in recombinant protein production and are 
summarized elsewhere (Vallejo & Rinas, 2004, Singh & Panda, 2005, Freydell, et al., 
2007, Burgess, 2009, Simpson, 2010, Basu, et al., 2011, Yamaguchi & Miyazaki, 2014, 
Singh, et al., 2015).  
The lack or poor solubility of recombinant proteins produced in bacteria is a 
multifactorial event. Which different genetic and environmental parameters (that is, 
bacterial culture conditions) and how they might be involved in the aggregation 
process have been a matter of controversial discussions, especially regarding the 
application of palliative measures (Sorensen & Mortensen, 2005, Sorensen & 
Mortensen, 2005). Recombinant protein aggregation is associated to incomplete or 
inadequate protein folding (Hlodan, et al., 1991), the consequent occurrence of 
exposed hydrophobic patches (Murby, et al., 1995), the inability of the cell quality 
control machinery (mediating both folding and proteolysis) to accurately perform 
under protein overproduction conditions  (Tomoyasu, et al., 2001, Baneyx & Mujacic, 
2004), the triggering of cell responses to conformational stress (Gasser, et al., 2008), 
an inappropriate codon usage (Parret, et al., 2016) and the molecular overcrowding 
associated to high protein yields in recombinant bacteria (Martinez-Alonso, et al., 
2008). The frequent heterologous origin of the recombinant polypeptides is also 
favouring aggregation, often due to the absence or inadequate posttranslational 
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modifications executed by bacterial cells that might be critical to adopt a native 
conformation (Schmidt, 2004, Demain & Vaishnav, 2009).  
Bacterial IBs are mainly composed of the recombinant protein that is accompanied by 
some/relatively few host cell proteins and traces of other macromolecular 
contaminants, such as lipids and nucleic acids (Rinas & Bailey, 1992, Fahnert, et al., 
2004). IBs are not mere clustered protein deposits, as the recombinant protein is not 
associated in an amorphous form, but structured as formerly unexpected amyloidal 
architectures (Carrio, et al., 2005, Cano-Garrido, et al., 2013), as discussed below. 
Amyloidal structures are formed through sequence-dependent, stereospecific 
interactions (Speed, et al., 1996) that exclude protein-protein associations between 
different protein species in a single aggregate (Morell, et al., 2008). IB formation in 
recombinant bacteria, based on such recruitment of homologous polypeptide chains is 
an extremely dynamic process (Carrio, et al., 1998, Carrio, et al., 1999, Carrio & 
Villaverde, 2001, Carrio & Villaverde, 2002, Baig, et al., 2014), that results from an 
unbalanced equilibrium between protein association and deposition, proteolytic 
digestion and disaggregation (Carrio, et al., 1999, Carrio, et al., 2000, Carrio & 
Villaverde, 2001, Carrio & Villaverde, 2002). This complex process is mediated by the 
arms of the quality control cell machinery that handle protein aggregates (Weibezahn, 
et al., 2004, Mogk, et al., 2018). In this way, the arrest of recombinant protein 
synthesis in metabolically active cells promotes the physiological disintegration of IBs. 
This is a fast process that results in the refolding of the protein into the native 
conformation (Carrio & Villaverde, 2001, de Marco, 2007) but also in the proteolytic 
digestion of an important fraction of the IB material (Carrio & Villaverde, 2001, Carrio 
& Villaverde, 2002). The integration of IB protein within the cellular quality control is 
also demonstrated by the conformational rearrangements observed within the IB 
particles (Gonzalez-Montalban, et al., 2008, Elia, et al., 2017).  
Although this is a still moderately understood issue, IB formation causes or it is linked 
to conformational stresses in the producing bacterial cell (Gasser, et al., 2008) and 
aggregated species are suspected to show some extent of intrinsic toxicity that might 
negatively affect bacterial cell growth. However, when eukaryotic cells are exposed to 
IBs in suspension or these particles are administered to whole organisms through 
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different routes, including injection or oral administration, IBs do not appear to be 
harmful (Garcia-Fruitos, et al., 2009, Diez-Gil, et al., 2010, Garcia-Fruitos, et al., 2010, 
Liovic, et al., 2012, Seras-Franzoso, et al., 2012, Vazquez, et al., 2012, Seras-Franzoso, 
et al., 2013, Seras-Franzoso, et al., 2013, Tatkiewicz, et al., 2013, Seras-Franzoso, et al., 
2014, Seras-Franzoso, et al., 2014, Seras-Franzoso, et al., 2015, Cespedes, et al., 2016, 
Seras-Franzoso, et al., 2016, Torrealba, et al., 2016, Torrealba, et al., 2016, Unzueta, et 
al., 2017, Stamm, et al., 2018, Unzueta, et al., 2018). Therefore, IBs have gained 
interest as intriguing  biocompatible protein materials (Villaverde, 2012, Villaverde, et 
al., 2012, Loo, et al., 2015, Seras-Franzoso, et al., 2015, Rinas, et al., 2017) that might 
be substantially different from protein aggregates linked to prion diseases or to 
degenerative disorders (Chiti & Dobson, 2017, Hartl, 2017). In this regard, IBs 
represent a paradigmatic example of non-toxic amyloids, associated with a diversity of 
functions and whose prevalence in living beings seems to be more spread than 
previously expected (Badtke, et al., 2009, Maji, et al., 2009, Romero & Kolter, 2014, 
Villaverde, et al., 2015, Jacob, et al., 2016, Molina-Garcia, et al., 2016, Dragos, et al., 
2017, Hewetson, et al., 2017, Jackson & Hewitt, 2017, Piscitelli, et al., 2017, Shin & 
Cherry, 2017).  
In 2005, it was reported that IBs are at least partially composed by functional protein 
(Garcia-Fruitos, et al., 2005, Jevsevar, et al., 2005) (Figure 1C). The fraction of 
functional polypeptides is not externally attached to the protein particles but it 
represents a structural part of the aggregates, being stable and tightly linked to IBs in 
aqueous solvents (Garcia-Fruitos, et al., 2007). The fact that an important fraction of 
the IB-embedded protein retains its biological activity (Gonzalez-Montalban, et al., 
2007) and that solubility and functionality are not equivalent parameters (Garcia-
Fruitos, et al., 2007) have allowed to further explore IBs as immobilized enzymes for 
catalysis (Hrabarova, et al., 2015), as biocompatible materials for tissue engineering 
(Garcia-Fruitos, et al., 2009, Seras-Franzoso, et al., 2012, Tatkiewicz, et al., 2013, 
Tatkiewicz, et al., 2018) and as protein delivery agents for in vivo applications (Garcia-
Fruitos, et al., 2012, Rinas, et al., 2017). Despite the exponentially growing number of 
examples supporting that IB functionality is a generic and transversal concept 
(Villaverde, et al., 2015), it still remains unfamiliar to an important fraction of the 
10 
 
scientific community that retains the obsolete concept linking protein solubility and 
functionality (Figure 1D). The bases of IB protein biological activities and the resulting 
applicability of IBs as functional materials will be discussed below.   
 
2.1 IBs are depot-type bacterial amyloids 
The combination of a significant set of amyloid-like properties (Ventura & Villaverde, 
2006) and the occurrence of biological activity of IB protein (Garcia-Fruitos, et al., 
2005) suggests a specific type of non-toxic functional amyloids, apparently uncommon 
in bacteria. Non-toxic functional amyloids have been widespread found in living beings 
including bacteria (Seviour, et al., 2015, Dragos, et al., 2017, Van Gerven, et al., 2018). 
They perform a significant set of recognized functions necessary for or favourable to 
cell or organic functions, though the activation/inactivation of defined cell circuits. 
These activities include catalysis, regulation of gene expression, control of DNA 
replication, signalling, mechanical structuring and complex functions at the systems 
level such as memory and reproduction (Hafner Bratkovic, 2017, Hewetson, et al., 
2017). In bacteria, amyloids have been associated to biofilm formation and quorum 
sensing (Schwartz, et al., 2012, Seviour, et al., 2015, Schwartz, et al., 2016, Stenvang, 
et al., 2016, Besingi, et al., 2017, Dragos, et al., 2017), virulence and toxicity 
(Marcoleta, et al., 2013, Syed & Boles, 2014, Van Gerven, et al., 2018), plasmid 
replication (Molina-Garcia, et al., 2016), bioenergetics (Molina-Garcia, et al., 2017) and 
transcriptional regulation (Pallares, et al., 2015, Yuan & Hochschild, 2017, Kaur, et al., 
2018), among others. In these examples, the target protein is found in two alternative 
conformational versions, namely amyloid and non-amyloid, that represent the ON-OFF 
states of molecular switchers. The coexistence of native or native-like and amyloidal 
forms of recombinant proteins in bacterial IBs places these particles out of this 
category. However, there are significant functional and structural similarities between 
bacterial IBs and secretory granules in the endocrine system. These are functional 
amyloids that act as repositories of peptidic hormones that are released from glands 
upon defined stimuli (Maji, et al., 2009). As far as we know, IBs are the first fully 
characterized depot-type amyloids found in bacteria. This amazing architecture, 
explained in next sections, make them particularly appealing as fully tailored 
11 
 
manufactured protein depositories that can be obtained by standard protein 
production procedures in recombinant cells. 
 
3. Protein aggregation as soluble protein aggregates  
As mentioned above, according to an assumption still largely accepted among 
biologists, soluble proteins correspond to monodispersed, native, and fully functional 
proteins. This simplification contrasts with both the evidence that soluble aggregates 
have a critical role in vivo in the progression of neurodegenerative diseases (Gerson, et 
al., 2014, Kumar, et al., 2016) and the data collected studying recombinant proteins. In 
two seminal papers (Nomine, et al., 2001, Nomine, et al., 2001) it was demonstrated 
that recombinant fusion constructs (composed by carriers such as GST, maltose-
binding protein or thioredoxin, known for their solubility plus the target proteins) 
expressed in E. coli and designed to improve overall yield, could form soluble micellar 
aggregates. These were described as composed by an aggregated nucleus originated 
by the condensation of hydrophobic patches made available by the misfolded target 
protein and by an external layer made of hydrophilic, highly soluble carrier protein 
(Figure 2 A). The overall structure remained soluble, but the functionality of the target 
protein was partially or totally lost. This condition can be very frequent when a 
difficult-to-produce protein is fused to a “solubilizing” partner, but can arise also when 
multi-domain proteins with components characterized by differing aggregation 
propensity are produced (Souillac, 2005). It must be also stressed that protein 
aggregation inside bacterial cells is an extremely dynamic process regulated by both 
chemical (osmolytes) and molecular chaperones (Singer & Lindquist, 1998, Carrio & 
Villaverde, 2001, Mogk, et al., 2003, Schultz, et al., 2007, Natalello, et al., 2008). 
Chaperone availability influences the process of aggregation, the structural 
characteristics of the aggregates, and their re-solubilisation into less complex or even 
native monodispersed molecules (Figure 2 B). In some cases, protein (re)folding to the 
native conformation is not achieved and chaperones stick to partially misfolded 
proteins, impairing their further condensations into larger aggregates (de Marco, et al., 
2000).  
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Nevertheless, the proteins complexed in these soluble aggregates are neither native 
nor fully functional. The contamination with GroEL and DnaK (easily detected by SDS-
PAGE) is a strong indicator that recombinant target proteins expressed in E. coli are at 
least partially unfolded/misfolded (de Marco, et al., 2000). The data collected in the 
last 20 years using recombinant proteins and controlled conditions show that in the 
same protein preparation it is possible to identify different soluble aggregates with 
increasing level of structural complexity, functionality, and capacity to interfere with 
cell metabolism (Calamai, et al., 2005, Schrodel & de Marco, 2005, Ami, et al., 2009, Li, 
et al., 2009). Multi-step sucrose gradients, native-blue electrophoresis and electron 
microscopy analyses enabled to appreciate the large structural variety of soluble 
aggregates recovered from samples purified from bacteria with different genetic 
background, grown at different conditions, and challenged with alternative stress 
factors (Stegemann, et al., 2005, Natalello, et al., 2008, Liu, et al., 2013). Part of the 
proteins trapped in these aggregates remains functional and these proteins are in a 
dynamic equilibrium with both monodispersed (native) forms and conventional 
(insoluble) IBs (de Marco, et al., 2005, Stampolidis, et al., 2009, Van der Henst, et al., 
2010). The kinetic of aggregate formation suggests that aggregation proceeds 
progressively into denser forms once the bacterial folding machinery is overwhelmed 
and osmolytes become limiting (de Marco, et al., 2005, Stampolidis, et al., 2009, Van 
der Henst, et al., 2010). Intrinsically disordered proteins are particularly prone to be 
recruited during aggregate nucleation, for instance, by proteins such Huntingtin which 
possess poly-glutamine patches (Wear, et al., 2015). The aggregation process can be 
minimized in vivo by tuning the cell culture parameters. This can be done according to 
the information inferred from “aggregation probes”, which quantify the relative 
aggregation level at different growth conditions (Schultz, et al., 2006, Paul, et al., 
2015). It means that native monodispersed proteins will be produced when the 
expression rate remains below the maximal capacity of the bacterial cells to fold the 
specific polypeptide. Under this perspective it must be considered all those 
precautions that reduce the cell growth rate (low temperature). These include the 
controlled increase of foldases and molecular chaperones (induction of stress response 
by ethanol/ benzyl alcohol addition or heat shock, overexpression of recombinant 
molecular chaperones), or the stabilization of the folding intermediates (chemical 
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chaperones) (de Marco, et al., 2005). Post-harvesting steps are also relevant since 
purification, storage, and stress conditions strongly influence the formation and the 
nature of soluble aggregates (Natalello, et al., 2009, Lebendiker & Danieli, 2014, Guo, 
et al., 2015, Smirnova, et al., 2015), and particularly, the aggregation process of 
intrinsically disordered proteins and proteins with intrinsically disordered regions 
(Churion & Bondos, 2012, Lebendiker, et al., 2015). Osmolytes of different chemical 
compositions have been effectively exploited to prevent the progressive formation of 
inactive soluble aggregates of therapeutic proteins (Liu, et al., 2013). The contribution 
of other components of cell chemical environment, such as salts and nucleic acids, to 
protein stability and aggregation has been reported (Futami, et al., 2014, Song, 2017), 
but is still largely unappreciated. What is clear but often underestimated, is that data 
obtained using protein preparations of soluble aggregates can be totally misleading 
(Nomine, et al., 2001). Consequently, protein quality control guidelines have been 
proposed to evaluate biophysical and functional features of soluble proteins and to 
prevent the use of material that is not suitable for both research and biotechnological 
applications (Paul, et al., 2015). Size exclusion chromatography (SEC) is the most 
accessible method to assess the presence of oligomeric forms and soluble aggregates 
in a sample. Large aggregates usually show a peak corresponding to the void volume 
and can be directly separated by native species (mono or oligomeric). Multi-angle light 
scattering (MALS) coupled to SEC or asymmetrical flow-field flow fractionation (AF4) 
results in more precise information and has been conveniently used to evaluate the 
effect of expression, purification, and storage protocols on the monodispersity of 
recombinant proteins (Zhou, et al., 2006, Pavisic, et al., 2010, Chen, et al., 2016, 
Amartely, et al., 2018). Dynamic light scattering (DLS) is another standard technique 
available for measuring the size of particles in solution and frequently used for 
detecting the presence of protein soluble aggregates. However, it has been criticized 
for its bias towards larger aggregates and alternative methods such as Taylor 
dispersion analysis have been suggested (Hulse, et al., 2013).  
 
4. Protein aggregation as IBs  
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Since their discovery as a common outcome during overexpression of heterologous 
proteins in E. coli, the perception on the composition and structure of IBs has 
dramatically changed. The aggregation process was not reversible by simple dilution of 
the polypeptide chains. Therefore, formation of protein aggregates in cell factories 
could not be attributed to a salting-out process as usually observed when proteins 
exceed their solubility limits. Moreover, it soon became obvious that active protein 
could be recovered following denaturation-renaturation protocols (Marston, 1986, 
Kane & Hartley, 1988, Schein, 1989). This suggested that the polypeptide chains within 
IBs were not covalently damaged and the information for reaching the native state was 
still present in the IB polypeptides. Due to the fact that IBs were formed starting from 
a vast diversity of recombinant proteins unrelated in sequence, size, structure and 
origin, it was initially thought that the chains engaged within the aggregates were 
adopting unfolded or misfolded conformations associated in a form of “statistical 
spaghetti”, that was escaping cell quality control.   
This was subsequently challenged by deep studies of the intracellular folding and 
aggregation of a unique model system at the time, the tailspike protein of 
bacteriophage P22. These revealed that aggregates originated from early, soluble 
partially folded intermediates in the folding pathway that could either proceed further 
to the native pathway or alternatively, form intermolecular aggregates (Haase-
Pettingell & King, 1988 ). The notion of the competition between productive and 
aggregation pathways was subsequently introduced, with the partitioning being 
dependent on temperature, concentration, etc.  This partitioning was also influenced 
by point mutations that were either favoring or disfavoring the aggregation pathway 
(Goldenberg & King, 1982 , Goldenberg, et al., 1983 , Yu & King, 1984, Yu & King, 1988, 
Mitraki, et al., 1991 ). The notion of specificity of aggregation has subsequently 
emerged when heterogeneous co-aggregates could not be observed in mixed 
renaturation experiments of entirely different proteins (Wetzel, 1994 , Wetzel, 1996, 
Betts, et al., 1997, Fink, 1998). This also implied that IBs were not amorphous protein 
deposits, but they were built through specific association of structural segments that 
could even retain “quasi-native” features (Mitraki & King, 1989, King, et al., 1996 Jan).   
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4.1 Amyloidal architecture of IBs 
It was well known that the target recombinant proteins were the major constituent of 
IBs (Ventura & Villaverde, 2006). However, their structural characterization in vivo was 
very challenging, due to the complexity of the folding and aggregation processes under 
molecular crowding conditions, the presence of heterologous proteins, and the 
dynamic nature of the process. Many methods for the characterization of protein 
aggregates can be applied only to dilute protein solutions in vitro and were not 
suitable to evaluate the insoluble, quasi-solid nature of the IBs. The first structural 
insights became possible thanks to Fourier Transform Infrared Spectroscopy (FTIR) that 
evidenced how  IB fractions displayed either increased intermolecular beta-sheet 
structure or, alternatively, native-like spectra. This suggested the occurrence of both 
amyloidal protein forms and folded polypeptides (Oberg, et al., 1994, Przybycien, et 
al., 1994, Fink, 1998). The possibility of recording FTIR spectra in intact cells enabled 
also following the kinetics of IB formation in real time (Ami, et al., 2005, Ami, et al., 
2006).  In a landmark 2005 study, it was reported that IBs had intermolecular beta-
structure as probed by FTIR and were binding to amyloid-diagnostic dyes such as 
Congo Red and Thioflavin T (Carrio, et al., 2005). Moreover, following extraction from 
cells, they were able to seed formation of amyloid fibrils from homologous soluble 
counterparts in vitro, suggesting an amyloid-like character (Carrio, et al., 2005). In 
subsequent electron microscopy studies, freshly extracted IBs appeared as electron 
dense, round objects from which fibrillar structures were occasionally emanating 
(Figure 3A). These fibrillar structures became more evident after treatment with 
proteinase K (Morell, et al., 2008).  X-ray fiber diffraction studies showed the 
characteristic cross-beta pattern, confirming the amyloid structure of the material 
(Wang, et al., 2008). When model fluorescent proteins such as GFP were fused to short 
aggregating peptides, such as Alzheimer’s Aβ42 or the foot-and-mouth disease VP1 
capsid protein, the formed IBs retained fluorescence. This fact indicated that 
aggregation was driven, and that it exclusively involved the aggregation-prone 
peptides. The fusion moieties represented by the intrinsically soluble GFP remained 
free to adopt native structure inside the protein clusters (Garcia-Fruitos, et al., 2005). 
The preference for aggregation in vivo of molecules belonging to the same species was 
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addressed by Fluorescence Energy Transfer (FRET) experiments of fusion proteins 
expressed in E coli cells. FRET is a sensitive method to probe close proximity of 
fluorescent proteins since it occurs between two fluorophores when located in the 
range of 10-100 Å from each other. Three-fold higher FRET was observed when two 
different fluorescent proteins were fused to the same aggregation-driving domain (ie 
either Aβ42 or VP1) compared to FRET observed upon co-expression of fusions of the 
same fluorescent proteins to two different aggregation domains. Thus, the 
requirement for sequence similarity for aggregation reinforced the notion of the 
stereospecific intermolecular contacts driving IB formation (Morell, et al., 2008).  
Sequence-specific structural information on the aggregated material  was then made 
possible thanks to the development of methods such as Hydrogen/Deuterium  
exchange coupled with Nuclear Magnetic Resonance (NMR) and solid-state NMR 
(Wang, et al., 2008).  Regardless of the initial conformation of the starting proteins, 
short (7-10 amino acids) stretches were found to form segments protected from 
hydrogen-exchange and able to mediate intermolecular beta-structure and IB 
formation (Wang, et al., 2008). IBs formed from the prion domain of the Het-s protein 
from the filamentous fungus Podospora anserina and amyloid filaments formed  by the 
same domain in vitro share the same amyloid structure as suggested by solid-state 
NMR studies (Wasmer, et al., 2009). The conformation of selected residues within IBs 
formed by Influenza virus hemagglutinin expressed in E. coli was studied with solid-
state NMR in whole cells and native-like, alpha helical conformation was reported for 
four selected residues (Curtis-Fisk, et al., 2008). Short sequences engaged in beta-
amyloid structures could apparently coexist with native – like conformation originated 
from the rest of the polypeptide chain, or parts of it.   
The latest perception on the structure of IBs converges towards a model where beta-
sheet, amyloid-structured parts and native-like, or even biologically active parts coexist 
(Gonzalez-Montalban, et al., 2007, Villaverde, et al., 2015). This conveys both 
mechanical stability and functional properties, allowing recovery of biological activity 
with a combination of mild solubilization conditions and traditional denaturation-
renaturation protocols (Peternel, et al., 2008, Singh, et al., 2015). Finally, the 
application of analytical methods such as contact angle measurements, zeta potential 
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and nanoindentation allowed the evaluation of IB wettability, surface properties, and 
stiffness (Diez-Gil, et al., 2010). Thus, the view of IBs as particulate, porous and highly 
hydrated bio-nanomaterials with interesting biological properties and a high 
mechanical stability has recently emerged. This awareness opened unexpected and 
promising avenues for IB use as immobilized biocatalysts, tissue engineering 
bioscaffolds or nanopills for controlled protein drug release (for reviews, see  (Mitraki, 
2010, Garcia-Fruitos, et al., 2012, Loo, et al., 2015, Rinas, et al., 2017)), as discussed in 
following sections. 
 
4.2 Biophysical nanoscale properties of IBs  
As discussed above, the target recombinant protein is the  major component of 
bacterial IBs (Neubauer, 2006). Its relative abundance in IBs varies according to the 
amino acid sequence (Peternel, et al., 2008) and it also depends on the conditions of 
bacterial culture and gene expression (Strandberg & Enfors, 1991, Baig, et al., 2014, 
Bakholdina, et al., 2018). Bacterial strains with mutations affecting protein folding and 
metabolism (e.g. deficiencies in the chaperones DnaK and ClpA, or in the cytosolic 
protease ClpP), also influence the IBs content (Carrio & Villaverde, 2003, Martinez-
Alonso, et al., 2008, Garcia-Fruitos, et al., 2012), that in turn impact on several 
biophysical and chemical properties of IBs and on their use as nanomaterials (Diez-Gil, 
et al., 2010).  
In this context, the shape and size of IBs are very much dependent on the particular 
target protein, the host bacterial strain as well as the production time (Garcia-Fruitos, 
et al., 2009, Diez-Gil, et al., 2010, Garcia-Fruitos, et al., 2010). Different authors 
described slightly different IB shapes, from spherical to ellipsoidal, cylindrical and even 
tear-shaped (Bowden, et al., 1991, Carrio, et al., 2000, Garcia-Fruitos, et al., 2007, 
Garcia-Fruitos, et al., 2010, Peternel & Komel, 2010), with a diameter that is limited by 
the size of the bacterial cell and ranges from 50 nm (probably the detection limit under 
optical microscope) to about 1,000 nm (Peternel, et al., 2008, Garcia-Fruitos, et al., 
2010). On the other hand, the size of the IBs is significantly reduced in vitro in low pH 
buffers as the result of an irreversible contraction process (Peternel, 2008). This 
peculiar condensation event affects the density and solubility of the IBs and it might be 
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of relevance for further in vitro and in vivo applications of IBs as materials. After 
isolation from bacterial cells, they are stable and can be stored for long periods at 4 °C, 
frozen at -80°C, or lyophilized, keeping the original IB architecture and the biological 
activity of the embedded proteins (Garcia-Fruitos, et al., 2009).  
IB proteins are usually not released in physiological buffers (Garcia-Fruitos & 
Villaverde, 2010), and such compositional stability is the basis for the exploitation of 
enzymatically active IBs as reusable catalysts (Krauss, et al., 2017, Rinas, et al., 2017). 
This concept of IBs as self-immobilized enzymes shows room for further improvement 
regarding operation reusability (Koszagova, et al., 2018), scalability (Kloss, et al., 2018) 
and functional complexity (Jager, et al., 2018). However, a fraction of IB protein is 
released from IBs in aqueous solutions (Garcia-Fruitos, et al., 2007, Unzueta, et al., 
2018), and the extent of such removable protein population appears to be dependent 
on the nature of the target protein, which influences the percentage of native-like IB 
protein. It is also dependent on factors such as the genetic background of the producer 
strain and the pH of the storage buffer (Garcia-Fruitos, et al., 2012). As materials, some 
IBs are loose, and as indicated earlier they can be dissolved by mild detergents or high 
pH buffers (Jevsevar, et al., 2005). This condition represents an opportunity to recover 
soluble IB protein in vitro avoiding protein denaturing agents (Singh, et al., 2015, Singh, 
et al., 2015). The particular sensitivity of IBs to such buffers and other mild-to-harsh 
treatments must be carefully considered to preserve the IB structure during 
purification (Rodriguez-Carmona, et al., 2010, Rodriguez-Carmona, et al., 2011, Seras-
Franzoso, et al., 2015), especially if intended for use as functional materials.  
The modification in the host cells of the genetic background relative to components 
involved in the protein quality control impacts not only on the efficiency of protein 
removal from IBs, but also on their functionality and physicochemical parameters such 
as zeta potential (surface charge) (Novak, 2009, Diez-Gil, et al., 2010), stiffness 
(elasticity) (Diez-Gil, et al., 2010) and wettability (ability of an aqueous liquid to 
maintain contact with IBs’ surface) (Diez-Gil, et al., 2010). For instance, IBs recovered 
from wild type cells are homogenous, while in DnaK- and ClpA- cells two IB populations 
with distinguishable stiffness and which remained segregated were produced (Diez-Gil, 
et al., 2010). These mechanical properties are extremely important when using IBs as 
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anchoring structures for the cultivation of the mammalian cells (Diez-Gil, et al., 2010, 
Seras-Franzoso, et al., 2012, Seras-Franzoso, et al., 2013, Tatkiewicz, et al., 2013, 
Tatkiewicz, et al., 2018), as stiffer IBs better stimulate cell attachment and/or 
proliferation (Novak, 2009).   
 
5. Physiology of IB formation  
Protein aggregates formed in recombinant bacteria are not mere passive deposits of 
insoluble protein, but the result of complex active physiological processes that link 
protein folding, quality control, conformational stress and amyloid formation. The 
physiology of IB formation is still far to be precisely dissected but the comprehension 
of the process has progressively increased. 
 
5.1 Energetics of IB formation  
IBs are usually found at the polar sites of the cell and it is generally accepted that polar 
preference of IBs or other protein aggregates can be attributed to macromolecular 
crowding in the midcell nucleoid region (Lindner, et al., 2008, Winkler, et al., 2010, 
Coquel, et al., 2013, Gupta, et al., 2014, Neeli-Venkata, et al., 2016, Oliveira, et al., 
2016). Occasional midcell detection of IBs can be explained by nucleoid-free regions at 
potential future septation sides (Winkler, et al., 2010, Coquel, et al., 2013). The 
hypothesis of crowding-provoked polar preference has never been challenged but the 
way protein aggregates reach the poles has been a matter of controversial debate as 
contradicting results were obtained suggesting an either energy-independent or 
energy-dependent mechanism.  
For example, it was demonstrated that polar localization of aggregates occurred also in 
energy-deprived cells, indicating a passive mechanism for polar positioning (Winkler, et 
al., 2010). Also, experimentally observed movements of age-related aggregates 
towards the poles were explainable with passive diffusion of aggregates and spatially 
non-homogeneous macromolecular crowding (Coquel, et al., 2013). On the other 
hand, there was also evidence that transport of aggregates to the poles can be an 
energy-driven process or at least dependent on metabolic activity (Rokney, et al., 
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2009, Govers, et al., 2014, Govers, et al., 2017). In this context, studies on cells with 
pressure dissociated IBs revealed that reassembly of small aggregates into large IBs did 
occur in cells exposed to fresh nutrients but not in energy and nutrient depleted cells 
(Govers, et al., 2014).  
These seemingly contradictive findings relatively to purely diffusive movement or 
energy-driven transport of aggregates towards the cellular poles become 
understandable by considering the glassy nature of the bacterial cytoplasm. Physical-
chemical studies have shown that metabolic activity is required to maintain fluidity in 
the cytoplasm, a condition necessary for the movement of larger particles (> 30 nm) 
(Parry, et al., 2014). Thus, it is reasonable to guess that it is not the active ATP-
dependent transport of aggregates but rather the fluidizing properties of active 
metabolism which facilitate movements of aggregates towards less crowded regions. 
Passive diffusion of aggregates towards the pole, a region of less macromolecular 
crowding, would then depend on the fluidity of the cytoplasm as well as on the initial 
size of aggregation foci. Smaller aggregation foci could move to the poles by diffusion 
also in energy-deprived cells, but larger aggregation foci could only reach the poles in 
metabolically active cells (Govers, et al., 2014). Polar distribution of IBs or damaged 
proteins can be considered as an evolutional benefit compared to unbiased dilution of 
misfolded and aggregated proteins as continued cell division leads to rejuvenation 
(Lindner, et al., 2008, Rokney, et al., 2009, Winkler, et al., 2010).  
 
5.2. Quality control and IB formation 
The bacterial protein quality control machinery, composed by a complex catalogue of 
chaperones and proteases with overlapping activities, has an important role in protein 
folding and refolding in the bacterial cytoplasm during conformational (thermal) 
stresses and especially during the production of aggregation-prone recombinant 
proteins. DnaK/DnaJ/GrpE (the KJE set), GroELS, ClpB, and IbpAB are main chaperones 
acting during this process (Figure 2 B) and they are over-produced under recombinant 
protein production (Allen, et al., 1992, Rinas, 1996, Veinger, et al., 1998, Goloubinoff, 
et al., 1999, Houry, 2001, Mogk, et al., 2003, Jurgen, et al., 2010, Zblewska, et al., 
2014). As these chaperones might be limiting for proper protein folding, many 
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biotechnologists have been exploring their co-production along with the recombinant 
protein, aiming at optimizing the production of soluble and properly folded soluble 
species (Sorensen & Mortensen, 2005, Sorensen & Mortensen, 2005, Kolaj, et al., 
2009). However, the role of chaperones and proteases goes beyond the strict control 
of the correct folding and refolding of misfolded soluble proteins. It has been widely 
proven that soluble and insoluble (aggregated) proteins are in a dynamic equilibrium 
between protein deposition and removal (Schrodel & de Marco, 2005) and the protein 
quality control machinery controls not only protein aggregation, but also protein 
quality in both soluble and aggregated fractions (Garcia-Fruitos, et al., 2007, Rinas, et 
al., 2007, Baig, et al., 2014). Specifically, it has been described that pivotal chaperones 
such as DnaK, GroEL, and ClpB (heat shock proteins -Hsp-) and IbpAB (small heat shock 
proteins -sHsp-) are intimately associated with IBs, which confirms that they have an 
active role in the formation and disaggregation of these protein clusters (Allen, et al., 
1992, Mogk, et al., 2003, Mogk, et al., 2003, Mogk, et al., 2003, Carrio & Villaverde, 
2005, Jurgen, et al., 2010, Zblewska, et al., 2014). 
In this context, upon the arrest of de novo protein synthesis, different members of the 
protein quality control are actively involved in the disintegration of IBs (Carrio & 
Villaverde, 2001). In parallel, and more specifically, the coordinated action of ClpB 
(disaggregase), KJE, and sHsp promotes the removal of polypeptides from protein 
aggregates (Mogk & Bukau, 2004, Weibezahn, et al., 2004). DnaJ binds to the 
aggregate surface, and it recruits first DnaK and finally ClpB to form an energy-
dependent chaperone complex whose coordinated action promotes protein removal 
(Jurgen, et al., 2010, Aguado, et al., 2015, Aguado, et al., 2015). In absence of 
functional DnaK or ClpB, the disaggregation activity is minimized, while IbpAB mutants 
have just a mild effect on the disaggregation process (Mogk, et al., 2003, Mogk & 
Bukau, 2004, Gonzalez-Montalban, et al., 2008, Garcia-Fruitos, et al., 2010). This 
indicates that IbpAB is not essential in the disaggregation process, although its 
presence can notably enhance the action of ClpB/KJE (Mogk, et al., 2003, Mogk & 
Bukau, 2004).  On the other hand, protein disaggregation is clearly an ATP-driven 
process (Rokney, et al., 2009, Winkler, et al., 2010). For example, HtpG can interact 
with DnaK/DnaJ/GrpE to further promote refolding of aggregated proteins in an ATP-
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dependent manner (Genest, et al., 2011). Alternatively, ClpB can also assist in 
cooperation with DnaK/DnaJ/GrpE in ATP-driven refolding of aggregated proteins 
(Ben-Zvi, et al., 2004, Acebron, et al., 2009, Winkler, et al., 2010). The small heat shock 
proteins (sHSPs; IbpA/IbpB) stabilize and decrease the size of protein aggregates 
(Ratajczak, et al., 2009) thereby promoting their DnaK/DnaJ/GrpE and ClpB mediated 
refolding (Matuszewska, et al., 2005). The major disaggregating chaperones (DnaK, 
ClpB) (Winkler, et al., 2010) but also IbpA (Lindner, et al., 2008) co-localize at the poles 
and participate in the disintegration of polar aggregates (Rokney, et al., 2009).  
In absence of DnaK, IBs are unusually large (Figure 2B) and the specific activity of the 
forming protein is significantly higher than in the wild type E. coli strain (Gonzalez-
Montalban, et al., 2006, Garcia-Fruitos, et al., 2007, Rinas, et al., 2007). In contrast, 
GroEL and IbpAB mutant strains form IBs in which the trapped enzyme shows the same 
specific activity than that found in the wild type E. coli strain (Kuczynska-Wisnik, et al., 
2004, Garcia-Fruitos, et al., 2007, Rinas, et al., 2007). The genetic background has also 
been proven to determine the final morphology of IBs. While most of IBs have a 
spherical-like form, indicating a homogenous deposition and removal of protein on the 
whole IB surface, a particular tear-shape morphology has been observed in ClpP-
deficient bacterial cells (Garcia-Fruitos, et al., 2010). At this point it is important to 
emphasize that proteases such as ClpP and Lon play also a role in the IB formation and 
intracellular solubilization (Carrio & Villaverde, 2003, Garcia-Fruitos, et al., 2010). 
Surprisingly, once proteins are physiologically released from IBs, they are proteolyzed 
irrespective of if they are misfolded or properly folded (and consequently functional) 
(Garcia-Fruitos, et al., 2010). Such uncontrolled proteolysis is tightly regulated by 
DnaK, which is anchored to the IB surface (Carrio & Villaverde, 2005). In the absence of 
this chaperone, the proteolysis is significantly reduced (Garcia-Fruitos, et al., 2010). 
Moreover, an excess of DnaK by controlled overexpression in IB-producing bacterial 
cells has been suggested to inhibit proper in situ folding of proteins forming such 
aggregates (Gonzalez-Montalban, et al., 2008). It appears evident from this schematic 
summary that it is not sufficient inducing the overexpression of single (or combinations 
of) chaperones/proteases to improve automatically recombinant protein folding. 
Automatized approaches which enable a large array of expression combinations are 
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probably the most efficient approach to identify the optimal conditions for each single 
protein (Turchetto, et al., 2017).  
 
5.3 Controlled IB production  
As discussed in previous sections, the formation of IBs is dependent on the quality 
control system and linked to an orchestrated cell response to stress factors. The 
identification of these factors opened a door to the engineering of production 
processes to favour the formation of IBs with defined properties, by adjusting the 
parameters affecting their formation. Paradoxically, many of them were recognized 
during the attempts to enhance the yield of soluble protein (Sorensen & Mortensen, 
2005, Sorensen & Mortensen, 2005).  When visualizing the protein production process 
as a whole, the rate at which the proteins fold in the cell can be reduced by adjusting 
the growth temperature of the culture, the strength of the gene promoter or even the 
medium composition. In the first case, the growth rate of bacteria directly affects the 
metabolism of the cell and specifically protein synthesis (Bosdriesz, et al., 2015, 
Calcines-Cruz, et al., 2018, Wurm, et al., 2018). In the second scenario, both the 
transcription and translation rates for the nascent polypeptide are reduced improving 
the performance of the folding modulators in the same way.  In addition, the same 
effect has been observed when medium composition reduces the cell growth (Jhamb 
& Sahoo, 2012) or when the inducer concentration is added in limiting amounts 
(Rabhi-Essafi, et al., 2007). In the same line, the possibility to increase the yield of 
insoluble protein has been performed by the fusional addition of aggregation or pull-
down tags to the recombinant protein (Nahalka & Nidetzky, 2007, Zhou, et al., 2012, 
Costa, et al., 2014, Wang, et al., 2015, Jong, et al., 2017).  
 
5.4 Tailoring IBs 
IBs are formed during protein production processes carried out under very diverse 
culture conditions, targeted to a vast diversity of proteins and supported by multiple  
expression systems (Taylor, et al., 1986, Georgiou & Valax, 1999, Castellanos-Mendoza, 
et al., 2014). By comparing production conditions, it has been determined that protein 
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aggregation and IB formation are favoured by factors affecting the transcriptional and 
translational regulation of the recombinant protein. These include the number of 
copies of the target gene (gene dosage), the promoter strength and the extent of the 
induction stimuli, the reducing conditions of the cytosol of the bacteria and the 
physicochemical characteristics of each particular protein (Mitraki, et al., 1991 , 
Przybycien, et al., 1994, Carrio & Villaverde, 2005, Ventura & Villaverde, 2006, 
Ignatova, et al., 2007, Nahalka, et al., 2008, Wang, et al., 2008, Tyedmers, et al., 2010, 
Winkler, et al., 2010, Singh, et al., 2015). The environment can also influence IBs 
formation. In fact, during recombinant protein production, temperature, culture time, 
nature of the inducer, growth rate, agitation and pH (Table 1, and Supplementary 
Table 1), have a profound impact on architectonic IB properties such as size, inner 
structure, content of active protein and their potential for being released or solubilized 
(Garcia-Fruitos, et al., 2005, Garcia-Fruitos, et al., 2005, Margreiter, et al., 2008, 
Peternel, et al., 2008, Upadhyay, et al., 2012, Castellanos-Mendoza, et al., 2014, 
Krauss, et al., 2017, Valdez-Cruz, et al., 2017, Calcines-Cruz, et al., 2018). 
 
 
 
The increase in IB size has been related with progression of the culture time, being 
more noticeable in the first hours after recombinant protein synthesis induction 
(Carrio, et al., 1998, Margreiter, et al., 2008, Garcia-Fruitos, et al., 2009, Upadhyay, et 
al., 2012, Castellanos-Mendoza, et al., 2014). However, it has been demonstrated that 
IBs populations are dynamically varying respect to time, being able to increase and 
decrease in the same process (Castellanos-Mendoza, et al., 2014). Also a rapid 
bacterial growth rate enhances the aggregation and the accumulation of recombinant 
proteins as IBs (Iafolla, et al., 2008). During culture, the increase in inducer 
concentration (mostly exemplified by IPTG) tends to favour the growth of IBs by a 
hundred of nanometers (Luo, et al., 2006), while at lower concentrations causes a 
reduction of the IB size combined with higher density of the recombinant protein 
within them (Margreiter, et al., 2008, Jhamb & Sahoo, 2012).  
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On the other hand, temperature is a widely used parameter to externally manipulate 
protein aggregation. Growth of E. coli at low temperature (between 16 °C and 30 °C) 
minimizes the formation of IBs or enriches them with partially or fully folded proteins, 
enhancing their biological activity (Jevsevar, et al., 2005, de Groot & Ventura, 2006, 
Vera, et al., 2007, Peternel, et al., 2008). Likewise, low temperature enlarges the 
extractable protein fraction from IBs, through the steps of solubilization and 
renaturation (Jevsevar, et al., 2005, Peternel, et al., 2008). On the contrary, when 
cultures are maintained at 37°C (or higher), IB formation is promoted as well as an 
increase of impurities inside them (Strandberg & Enfors, 1991, Valax & Georgiou, 1993, 
Villaverde, et al., 1993). Even more, IBs formed at 42°C present greater resistance to 
solubilization and denaturation compared with those formed at 25°C, indicating that 
the culture temperature determines the conformational properties and stability of the 
proteins trapped within aggregates (Jevsevar, et al., 2005, de Groot & Ventura, 2006, 
Vera, et al., 2007, Peternel, et al., 2008).  
pH has also been examined regarding the formation and quality of IBs (Strandberg & 
Enfors, 1991, Castellanos-Mendoza, et al., 2014, Calcines-Cruz, et al., 2018). When the 
pH dropped below 5.5, an increase in the relative amount of IBs was observed 
compared with cultures developed at constant pH, upon temperature-mediated 
induction of recombinant gene expression (Strandberg & Enfors, 1991). Differences in 
the size and architecture of the IBs were determined when comparing bioreactor 
cultures under controlled pH (7.5) and uncontrolled pH. Those IBs formed under 
uncontrolled increasing alkaline conditions (up to 8.5) have a lower content of amyloid 
structures and are easier to solubilize using proteinase K or to denature by chaotropic 
agents if compared with those IBs recovered from bacteria cultured at controlled pH 
(Castellanos-Mendoza, et al., 2014). Similar results were found when IBs were 
produced under constant basic pH of 8.5, using different model proteins and genetic 
backgrounds (Calcines-Cruz, et al., 2018).  
The architecture and size of IBs can be also affected by oxygenation conditions of 
bacterial culture in shake flasks. When orbital (200 rpm) and resonant acoustic mixing 
(RAM at 20 g forces) were used, a decrease in IB size combined with higher number of 
small aggregates was observed throughout the cytoplasm. In addition, the smaller 
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bodies formed under these conditions were easier to solubilize, and showed 
enrichment in alpha helices compared with those formed under orbital agitation or 
under lower g forces in RAM (Valdez-Cruz, et al., 2017).  
Culture conditions represent factors to exploit for improving the IB characteristics 
according to the final applications foreseen for such “raw material”. For instance, the 
modification of process parameters allows adjusting the conformational (and 
functional) quality of the IB proteins and more efficient protein extraction (Peternel, et 
al., 2008, Dong, et al., 2014, Raghunathan, et al., 2014, Krauss, et al., 2017, Calcines-
Cruz, et al., 2018). 
 
6. Applicability of IBs as non-toxic, functional amyloids  
Bacterial IBs are mechanically stable protein materials (Garcia-Fruitos, et al., 2009). 
Such structural robustness is the basis for their emerging applications as a versatile 
microbial biomaterial in biomedicine (Rodriguez-Carmona & Villaverde, 2010) and 
specially as a topographic decorator in tissue engineering (Seras-Franzoso, et al., 
2015). The firm attachment of functional enzymes to the amyloidal scaffold of IBs 
(Cano-Garrido, et al., 2013) is, on the other hand, supportive of their application as 
self-immobilized catalysts (Rinas, et al., 2017). The differential sensitivity of amyloidal 
and non-amyloidal forms of IB proteins to proteinase K (Cano-Garrido, et al., 2013) 
confirms the dual structural composition of the materials, that might be linked to the 
occurrence of harder and softer areas in the particles (Diez-Gil, et al., 2010). 
 
6.1 Protein release from IBs  
The non-amyloidal fraction of IB protein appears being in a looser conformational 
status supported by weaker protein-protein contacts than the cross-molecular beta-
sheet architecture of the amyloidal fibril skeleton (Carrio, et al., 2005, Gonzalez-
Montalban, et al., 2006, de Groot, et al., 2009, Pesarrodona, et al., 2016, Rueda, et al., 
2016). Upon internalization by cultured mammalian cells (Figure 3B), an important 
fraction of IB protein is released from the particles (Figure 3C), probably supported by 
the action of cell factors, presumably chaperones (Seras-Franzoso, et al., 2016), in the 
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context of the evolutionarily conserved quality control machinery (Mogk, et al., 2018). 
The ability of this fraction of IB proteins to be released under physiological conditions 
has opened a spectrum of possibilities both in vitro and in vivo to (i) recover functional 
protein from IBs under non-denaturing conditions (Peternel, et al., 2008) and (ii) 
explore IBs as mimetics of secretory granules of the endocrine system for the 
sustained release of functional proteins in the body (Unzueta, et al., 2018), 
respectively.  
 
6.2 Controlled in vitro release of IB protein in biotechnology 
In the context of IB protein recovery, classical denaturation and renaturation 
procedures are time consuming and result into a limited, product-dependent recovery 
of the functional protein (Vallejo & Rinas, 2004). The recognition of IBs as 
nanoparticles composed by properly folded proteins prompted the investigation of 
simpler methods to extract them from the bulk material, as the disruption of the 
protein structure might be not required. In fact, washing IBs with physiological buffers 
with mild denaturants enables the removal of functional proteins in a single step 
procedure (Singh, et al., 2015).  
Producing IBs in conditions that favour proper protein folding (for instance, low growth 
temperatures) enriches them with functional polypeptides at expenses of amyloidal 
structure. However, these highly functional IBs can be quite fragile, and their isolation 
from bacterial cells becomes a critical step. Lysozyme commonly used for bacterial lysis 
can adhere to the IB surface, representing an additional and major impurity. On the 
other hand, sonication can cause the loss of the target protein, and  high-pressure 
homogenization has been recognized as the most suitable cell disruption method for 
looser IBs (Peternel & Komel, 2010). Upon IB isolation, mild detergents can be used for 
IB solubilization and high recovery rates of extremely pure and biologically active 
protein have been achieved in this way (Jevsevar, et al., 2005). In pioneering studies, 
various chemicals in slightly alkaline buffer (40 mM Tris/HCl, pH 8), that do not disturb 
the protein structure (5% n-propanol, 2 M urea, 0.5% Triton X-100, 0.2% NDSB, 5 % 
DMSO and 0.2% N-lauroyl-sarcosine) were tested to extract biologically active 
granulocyte colony stimulating factor (G-CSF) from IBs, representing up to 50 % of the 
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whole protein yield (Jevsevar, et al., 2005). Similar procedures for non-denaturing 
solubilization were later described for other proteins (Peternel, et al., 2008, Upadhyay, 
et al., 2014) (1,2,4,5).  Besides low concentration of chaotropes and mild detergents, 
also alkaline pH in combination with low concentration of urea (Singh, et al., 2015), 
high pressure (St John, et al., 1999), and organic solvents (Singh, et al., 2012) have 
been used for successful recovery of bioactive proteins from IBs (Singh, et al., 2015). 
(Singh, et al., 2015). On the other hand, mild extraction does not work for all IB 
embedded proteins; for instance, the bone morphogenetic protein 2 which still 
requires harsh extraction and subsequent refolding under appropriate redox 
conditions (Quaas, 2018). 
 
6.3 IB protein release in vivo for biomedicine 
The nanopill concept was around the idea that IBs, as functional protein-releasing 
amyloids, might be exploited for protein replacement therapies. In this context, IBs 
formed by functional proteins would physiologically rescue cells with deficiencies 
caused by either genetic (missing protein functions) or environmental (external 
stresses) conditions, by acting as carriers of proteins that re-establish cellular 
homeostasis. A deep interaction (and further embedment) between IBs and 
mammalian cell membranes in cultured cells was strongly suggesting that at least a 
significant fraction of IB material might be available intracellularly (Garcia-Fruitos, et 
al., 2009). As a proof of concept, IBs formed by dihydrofolate reductase, catalase, 
leukaemia inhibiting factor and Hsp70, once added to the medium of cultured cells 
were able to rescue cell viability in different experimental systems (Vazquez, et al., 
2012). In parallel, it was also demonstrated that IBs composed by the  structural 
cytoskeleton protein keratin 14 released enough correctly folded protein to form 
heterodimers together with the fluorescent keratin 5, and thus built up fluorescent 
precursors of the intermediate filaments in epithelial cells (Liovic, et al., 2012). Other 
interesting applications in regenerative medicine have emerged later, in the context of wound 
healing (Figure 3D, (Stamm, et al., 2018)). In this context, bacterial IBs appeared suitable 
also as structural and functional biomimetics of the secretory granules in the 
mammalian endocrine system by releasing protein hormones (urotensin, glucagon, 
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obestatin, bombesin and secretin among others, Figure 3A). Under physiological 
conditions these are kept in the body as amyloidal storage units to be released upon 
appropriate stimuli with the assistance of cell chaperones (Maji, et al., 2009).  
Subsequent studies have shown that nanopills are functional in delivering biologically 
active proteins not only upon free addition to the culture medium (top-down), but also 
when decorating surfaces on top of which cells grow (bottom-up) (Seras-Franzoso, et 
al., 2013). In this second case, nanopills act rather as bioactive topographic scaffolds or 
bioscaffolds (Seras-Franzoso, et al., 2013) with a dual effect. On the one side, they 
support cell proliferation due to physical stimuli promoted by modifications of the 
surface nanotopography and that favour both cell adhesion and the activation of 
proliferative cascades (Seras-Franzoso, et al., 2012). On the other hand, growth or 
differentiation protein factors released by IB can induce a direct biological effect. The 
functionalization of 2D and 3D structures with FGF-2 bioscaffolds favoured the growth 
and differentiation of epithelial cells, fibroblasts and neuron-like cells (Seras-Franzoso, 
et al., 2013, Seras-Franzoso, et al., 2013, Seras-Franzoso, et al., 2014). IBs releasing the 
lipoxygenase AmbLOXe have been recently proved to be effective in wound repair 
(Stamm, et al., 2018), in both nanopill and bioscaffold formats. 
The way through which nanopills and bioscaffolds perform their function is dual. 
Experimental data support protein released by IBs penetrating exposed cells and acting 
from within as well as accumulating in the culture medium and acting extracellularly. 
In this regard, free IBs interact tightly with the cell membrane through cell-emitted 
filopodia which promote IB internalization by micropinocytosis (Seras-Franzoso, et al., 
2012, Vazquez, et al., 2012, Seras-Franzoso, et al., 2016, U, et al., 2016). Although part 
of the IB protein is degraded in lysosomes, significant amounts of IB protein are still 
detectable intracellularly by immunohistochemistry, once released from IBs into the 
cytoplasm after the disruption of the endosomal membrane (Figure 3C, (Seras-
Franzoso, et al., 2016)). A similar event, although with additional steric constraints, 
probably occurs with bioscaffolds (Seras-Franzoso, et al., 2013). Interestingly, the 
biological effect of bacterial amyloids increases when IBs are produced at 
temperatures below 37 °C (Seras-Franzoso, et al., 2014). This is because the 
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conformational and functional quality of IB proteins is higher under these conditions 
(Vera, et al., 2007), as discussed above. 
A step forward in the design of improved nanopills has been the generation of cell 
targeted-IBs that preferentially bind to a specific cell type and enable targeted protein 
delivery. In this context, soluble glycoproteins have been covalently conjugated to 
therapeutic IBs for the recognition of adhesins on the surface of pathogens. A self-
cleaving peptide has been included to release the functional IB protein after pathogen 
recognition, creating in this way a pioneer tailored and active protein delivery platform 
(Talafova, et al., 2013). In a further step to tailor IBs, the fusion of a ligand for a cell 
surface receptor to the IB-forming protein enabled receptor-dependent IB 
internalization and cell targeted delivery without requiring chemical modifications of 
IBs after their purification  (U, et al., 2016).  
In vivo studies have proved the potential of IBs as protein releasing materials, 
mimicking the in vivo secretion of protein hormones.  This effect has been simulated 
by intratumoral injection and also as subcutaneous nanoimplantation of functional IBs 
in different murine cancer models. When fluorescent (GFP- or IRFP-based) IBs are 
injected intratumorally, the emission remains within the tumor for at least one week, 
and does not induce apparent side effects. This observation indicates that IBs might 
represent a stable local source for releasing functional protein without toxicity effect. 
In addition, in this pioneering experiment, there was a certain in situ antitumor effect 
derived from the tumor receptor blockade induced by the peptide T22 contained in 
the IBs and used as selective binder for the tumoral marker CXCR4 (Cespedes, et al., 
2016). In a more challenging approach, it was possible to demonstrate that IB protein 
could act systematically moving through the blood stream. As an intriguing platform, 
IBs formed by self-assembling proteins (Figure 3E) that organize as nanoparticles 
(Pesarrodona, et al., 2016, Unzueta, et al., 2018) were used. When such IBs were 
applied locally as subcutaneous implants far from the primary tumor in mice, the 
active protein was progressively and specifically transferred over a period of more 
than ten days from the injection site to the tumor (Unzueta, et al., 2018). This fact 
supports that IBs could be used in vivo as stable and biocompatible implantable 
materials for remote delivery of nanostructured protein drugs and materials (Figure 
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3F). The production of IBs and IB-like materials in endotoxin-free strains of E. coli  
(Rueda, et al., 2014), in food-grade gram positive acid lactic bacteria (Cano-Garrido, et 
al., 2014, Cano-Garrido, et al., 2016) and in conventional yeast factories (Rueda, et al., 
2016) will minimize the potential regulatory constraints for further in vivo applications 
of IBs. 
 
7. Conclusion 
Bacterial IBs were observed, since early times of recombinant protein technology, as 
an obstacle for the production of functional proteins. A limited comprehension of the 
protein production machinery wrongly positioned them as waste material excluded 
from the cell quality control, and catalogued IBs as protein clusters composed of 
irreversibly misfolded or unfolded polypeptides. Gaining insights about the physiology 
of recombinant cell factories and also about proteomics of protein aggregates shifted 
this original perception to the current status in which IBs are included in a specific 
category of functional amyloids. A particular combination of amyloid fibrils and 
functional structures of the recombinant protein confers to them intriguing properties 
as mechanically stable and functional materials. Such unusual features point out 
bacterial IBs as convenient models to study how functional amyloids (especially those 
used in nature as protein depots) are formed and structured but also enable their 
exploitation in different areas of biotechnology and medicine. IBs, as protein-releasing 
materials, are fully biocompatible, and their properties can be modulated through the 
genetic engineering of the employed proteins, of the host cells, and of the bacterial 
culture process. In such a way, it is possible to generate nanoparticles that can be 
targeted in vivo and used as source of functional protein.  
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Figure 1. Properties of bacterial IBs. A. Visualization of IB-producing E. coli cells by 
optical microscopy. IBs are refractile intracellular particles. B. Transmission electron 
microscopy images of IB-producing Lactococcus lactis cells. IBs are observed as 
electrodense materials in the cell cytoplasm. C. Phase contrast and fluorescent 
microscopy of the same field of a BFP-producing E. coli cell culture. Blue fluorescence 
is apparent. D. Classical model (up) in which a recombinant bacterial cell can be 
divided into two virtual fractions, namely the soluble cell fraction containing properly 
folded, soluble and functional protein (green), and the insoluble fraction containing 
aggregated, misfolded or unfolded non-functional protein (red). Experimental data 
have accumulated demonstrating that both soluble and insoluble cell fractions are 
formed by functional (green) and non-functional (red) protein versions (bottom). 
Culture and genetic conditions that improve protein folding improve the conformation 
quality of both soluble and insoluble protein species, while those impairing folding also 
impact on both cell fractions. Images are modified versions from (Carrio & Villaverde, 
2001) (A), (Cano-Garrido, et al., 2016) (B), (Garcia-Fruitos, et al., 2005) (C) and 
(Gonzalez-Montalban, et al., 2007) (D). Images have been reproduced with permission 
of Elsevier and Springer Nature. 
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Figure 2. Protein aggregation in recombinant bacteria. A. Characteristics of soluble 
micelles formed by fusion proteins. Fusions between a target protein (grey) with 
propensity to aggregate and a passenger polypeptide with high solubility (green) are 
expressed to increase the chance of the target protein to remain in suspension and 
complete its folding. Usually a linker (yellow) is exploited to connect the sequences to 
avoid steric hindrance between the two moieties during folding but it has been 
described as a sensitive portion for proteolytic degradation. Whether it is not the case 
and the aggregation-prone protein does not succeed to reach a stable folding, it will 
interact non-specifically with similar misfolded proteins. They will form a compact 
hydrophobic core surrounded by the highly soluble passenger molecules. The micelle-
like structures will therefore remain soluble in polar solutions. If the passenger 
proteins have dimerization capacity –as for instance the common passenger protein 
GST- they will promote the merge of single micelles to form larger aggregates which 
will still be able to float, at least until a critical point.  B. Protein misfolding, progressive 
aggregation, precipitation and re-solubilization. Proteins might need the support of 
osmolytes and molecular chaperones (DnaK/DnaJ/GrpE + GroESL) to reach their native 
folding, otherwise remain trapped into instable folding intermediates which can 
aggregate. Limiting chaperone capacity as well as stress conditions which induce 
protein misfolding can lead to aggregation mediated by hydrophobic patches present 
on the molecule surface and that tend to combine with other similar regions of the 
same or other proteins. The consequent instability leads to form progressively larger 
aggregates that can finally precipitate into IBs possessing heterogeneous composition 
(native, quasi-native, aggregate, amyloid-like conformations;  blue  
squiggles). At the same time, misfolded proteins and protein aggregates with variable 
levels of complexity can be rescued by the activity of chaperones (bidirectional 
arrows). Main E. coli cytosolic chaperones are shown as connected to the folding 
pathways. In absence of DnaK, IBs are significantly larger and they are formed by 
higher amounts of biologically active proteins.  
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Figure 3. Amyloid structure of IBs and their uses as protein-releasing materials. A. 
Bacterial IBs showing detached amyloid fibrils. Bars indicate 1 µm. At the bottom, 
amyloidal structure of two human hormones, showing their fibrillar organization raised 
during in vitro incubation. Bars represent 0.5 µm. B. GFP IBs (green) penetrating 
cultured mammalian cells, upon addition to culture media. In red, cell membranes and 
in blue, the nuclear region. C. Immunolabelling of released IB protein upon cell 
internalization of IBs present in the culture media. Bar represents 100 nm. D. Positive 
effects of IBs formed by an epidermal lipoxygenase in an in vitro wound healing model. 
The bottom image reflects the IB treatment. E. FESEM imaging of purified IBs formed 
by the self-assembling protein T22-GFP-H6. This protein forms nanoparticles of 11 nm 
(Rueda, et al., 2015), a size compatible with that of the small structures found 
surrounding the IB. These particles bind the cell surface tumoral marker CXCR4, though 
its specific ligand T22 (Unzueta, et al., 2012). F. When IBs described in E are injected 
subcutaneously in colorectal cancer mouse models, the amount of IB protein at the 
injection site decreases over time, while the amount of T22-GFP-H6 protein in tumor, 
released from IBs, increases. At the bottom, schematic representation of how T22-
GFP-H6, released from subcutaneously implanted IBs, reaches a primary CXCR4+ tumor 
in colorectal cancer mouse models. The full experiment is described elsewhere 
(Unzueta, et al., 2018). Images are reproduced or modified from (Wang, et al., 2008) 
(A, top), (Maji, et al., 2009) (A, bottom), (Villaverde, et al., 2012) (B), (Seras-Franzoso, 
et al., 2016) (C), (Stamm, et al., 2018) (D), (Unzueta, et al., 2018) (E, F). Images have 
been reproduced with permission of The American Association for the Advancement of 
Science, The Royal Society of Chemistry and Elsevier. 
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Table 1. Main properties of bacterial IBs adjustable through process conditions.   
Parameter IBs structure features Reference 
Culture time 
When culture time after induction increased, 
IBs median diameter augmented. Also, as the 
culture time passed, IBs showed strong binding 
with Congo red and Thioflavin-T (suggesting 
more amyloid content), and they became 
more resistant to proteolysis and 
denaturation. 
(Margreiter, et al., 
2008, Upadhyay, 
et al., 2012, 
Castellanos-
Mendoza, et al., 
2014) 
Inductor 
concentration 
Low concentration of inductor (IPTG) 
decreased the aggregation and hydrodynamic 
diameter. Some IBs increased in RP content 
under lower inductor concentration. 
(Luo, et al., 2006, 
Margreiter, et al., 
2008, Jhamb & 
Sahoo, 2012) 
Growth rate 
At low specific growth rates, less abundant IBs 
were found. However, more RP was present in 
IBs formed at the fastest growth rate. 
(Iafolla, et al., 
2008) 
Temperature 
IBs formed at low temperature presented 
some properly folded and active proteins, less 
impurities, and were solubilized and denatured 
faster than those formed at high temperature. 
Increase in temperature promoted RP 
aggregation and improved the IB production 
rate. 
(Schein & 
Noteborn, 1988, 
Strandberg & 
Enfors, 1991, 
Jevsevar, et al., 
2005, de Groot & 
Ventura, 2006, 
Peternel, et al., 
2008)  
pH 
Relative amount of IBs increased with the 
decline in pH during culture. IBs formed under 
basic pH, presented more a-helices, were less 
resistant to proteolysis and bonded less 
Thioflavin-T, vs. IBs produced at acidic pH. 
(Strandberg & 
Enfors, 1991, 
Castellanos-
Mendoza, et al., 
2014, Calcines-
Cruz, et al., 2018)  
Agitation 
Diffused protein clusters were seen inside cells 
cultured in shake flasks under acoustic 
resonant mixing at high energy (20 g) 
compared with IBs formed under orbital 
agitation. IBs at 20 g were less resistant to 
proteolysis. 
(Valdez-Cruz, et 
al., 2017) 
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Human interferon–α2 (IFN–α2); interferon–γ (IFN–γ); Human growth hormone (hGH); Xylanase 
(XynB); Alzheimer-related peptide Ab42 mutant fused to green fluorescent protein 
(Ab42(F19D)-GFP); green fluorescent protein (GFP); protein A from Staphylococcus aureus and 
I-galactosidase (SpA-gal); Isopropyl β-D-1-thiogalactopyranoside (IPTG); Not determined (N.D.); 
guanidinium chloride. (GnCl); Thioflavin-T (Th-T); Recombinant protein (RP). 
 
 
 
 
Supplementary Table 1. Properties of bacterial IBs adjustable through process conditions 
(extended version of Table 1).   
 
Parameter Culture conditions 
Recombinant 
protein  
(E. coli strain) 
S vs. 
IS 
(%) 
IBs structural features Ref. 
 
Bioreactor, fed-batch (37 °C), 
IPTG induction 
β-lactamase 
(K12, HMS174-
DE3) 
5-95 
IBs increased in median diameter from 
325 nm to 410 nm, 2 and 6 h after 
induction. 
(Margreiter, 
et al., 2008) 
Batch (37 °C), IPTG induction hGH (M15) N.D. 
IB size incremented from 200 up to 800 
nm after 4 h of induction. IBs showed 
strong binding with CR and Th-T, and 
were more resistant to proteolysis and 
denaturation. 
(Upadhyay, 
et al., 2012) 
Bioreactor, batch (37 °C), 
IPTG induction 
Sphingomyelin
ase-D (BL21-
Gold-DE3) 
3–
97 
IBs Increased in a median diameter 
from 450 nm (1 h post-induction) to 600 
nm (3 h post-induction). 
(Castellanos
-Mendoza, 
et al., 2014) 
 
Bioreactor, fed-batch (37°C), 
1.0 µM IPTG / g dry biomass β-lactamase (K12, HMS174-
DE3) 
2–
98 
Similar aggregation, increasing ~25 % 
RP content in IBs. (Margreiter, 
et al., 2008) Bioreactor, fed-batch (37°C), 
20 µM IPTG / g dry biomass 
5–
95 
Similar aggregation, lower RP content in 
IBs.  
Shake flask, batch (37 °C) 
0.01 mM IPTG XynB (BL21) 
13-
87 
Decreased aggregation. (Jhamb & 
Sahoo, 
2012) Shake flask, batch (37 °C) 1.0 mM IPTG 4-96 
Increased IB formation. 
Batch (37°C), 0.1 mM IPTG 
GFP 
N.D. Lower hydrodynamic diameter.  (Luo, et al., 
2006) Batch (37°C), 2.0 mM IPTG N.D. Hydrodynamic diameter increased from 550 to 645 nm. 
Growth rate Shake tubes, batch (37 °C) EGFP (DH5-alfa) N.D. 
~5-10 times more RP are in IBs at the 
fastest growth rate. 
(Iafolla, et 
al., 2008) 
 
Batch (30 °C), trp promoter IFN–α2 
(HB101) 
73-
27 
Less RP aggregation 
(Schein & 
Noteborn, 
1988) 
Batch (37 °C), trp promoter 5-95 Increase in temperature promoted RP aggregation 
Batch (30 °C), trp promoter IFN–γ (C600/l- 
lys) 
95-5 Less RP aggregation 
Batch (37 °C), trp promoter 18-82 
Increase in temperature promoted RP 
aggregation 
Bioreactor, batch (30°C in 
growth phase), 
thermoinduction at 39 °C SpA-β gal (RR1 
lacZAM15) 
N.D. Lower IBs formation at initial post-induction time. (Strandberg 
& Enfors, 
1991) Bioreactor, batch (30°C in growth phase), 
thermoinduction at 42°C 
N.D. 
The highest accumulation of IBs, 
formed mainly during the first hours 
after induction. 
Shake flask, batch (30°C), 0.1 
mM IPTG 
99–
1 
Less RP aggregation. 
Cu
ltu
re
 ti
m
e 
Te
m
pe
ra
tu
re
 
In
du
ct
or
 co
nc
en
tr
at
io
n 
Shake flask, batch (37 °C), 0.1 
mM IPTG OmpA-β-lactamase 
(RB791) 
60-
40 
Impurities were lower in IBs from 
cultures at 37 °C vs. 42 °C. The highest 
IBs concentration. 
(Valax & 
Georgiou, 
1993) Shake flask, batch (42°C), 0.1 
mM IPTG 
83-
17 
Temperature increase promoted IB 
formation. 
Batch (37 °C by 4 h), after 1 
mM IPTG cultures were set 
to 18 °C 
Ab42(F19D)-
GFP 
N.D. Less RP aggregation and high specific fluorescence. 
(de Groot & 
Ventura, 
2006) 
Batch (37 °C by 4 h), after 1 
mM IPTG cultures were set 
to 25°C 
N.D. 
The formed fluorescent IBs were 
solubilized and denatured faster by 
proteases and chaotropic agents, than 
those from cultures at 42 °C. 
Batch (37 °C by 4 h), after 1 
mM IPTG cultures were set 
to 37 °C 
N.D. 
Increase in temperature promoted IB 
formation and decreased their 
fluorescence 
Batch (37 °C by 4 h), after 1 
mM IPTG cultures were set 
to 42 °C 
N.D. 
Increase in temperature promoted IB 
formation and depleted their 
fluorescence. 
Shake flask, batch (25°C), 0.4 
mM IPTG 
G-CSF 2–98 
Proteins inside IBs formed at 25°C 
presented similar structure as the 
native versions, with increased 
extractability in mild detergents, 
compared with those from 37°C and 
42°C. 
(Jevsevar, et 
al., 2005, 
Peternel, et 
al., 2008) 
GFP 33-77 
His7dN6TNF-α 60-40 
pH 
Bioreactor, batch (30°C in 
growth phase, 
thermoinduction at 39°C) SpA-βgal (RR1 
lacZAM15) 
N.D. 
When pH decreased to ~5.5, IB 
accumulation was triggered, reaching 
up to 30 % of cell dry weight. (Strandberg & Enfors, 
1991) Bioreactor, batch (30°C in growth phase, 
thermoinduction at 42°C) 
N.D. 
When pH decreases to ~5.5, IBs 
formation increased vs. 39°C, reaching 
up to 75 % of cell dry weight. 
Bioreactor, batch (37 °C), 0.1 
mM IPTG. pH 7.5 Sphingomyelin
ase-D (BL21-
Gold-DE3) 
0-
100 
IBs were more resistant to proteolysis 
and denaturation.  (Castellanos
-Mendoza, 
et al., 2014) 
Bioreactor, Batch (37 °C), 0.1 
mM IPTG. pH uncontrolled 
(reach pH 8.5) 
0-
100 
IBs grown faster and were less resistant 
to proteolysis and denaturation. 
Bioreactor, batch (37 °C), 0.1 
mM IPTG. pH 7.5, and set to 
8.5 after induction 
Phospholipase 
A2 (OrigamiTM) 
0-
100 
IBs presented more a-helices, were 
solubilized faster by proteinase-K and 
bonded less Th-T. (Calcines-Cruz, et al., 
2018) Bioreactor, batch (37 °C), 0.1 mM IPTG. pH 7.5, and set to 
6.5 after induction 
Phospholipase 
A2 (OrigamiTM) 
0-
100 
IBs presented less a-helices, were less 
solubilized by proteinase-K and bonded 
more Th-T. 
Agitation 
Shake flask, batch (37 °C), 0.1 
mM IPTG, orbital (200 rpm) Phospholipase 
A2 (BL21-Gold-
DE3) 
0-
100 
IBs showed sizes of ~400 nm with less 
a-helices fraction, compared with those 
formed under resonant acoustic. (Valdez-Cruz, et al., 
2017) Shake flask, batch (37 °C), 0.1 
mM IPTG, resonant acoustic 
(20 g) 
0-
100 
Diffused protein clusters were seen 
inside cells. IBs at 20 g were the most 
degraded after 120 min.  
 
Human interferon–α2 (IFN–α2); Interferon–γ (IFN–γ); Human growth hormone (hGH); Xylanase 
(XynB); Alzheimer-related peptide Ab42 mutant fused to green fluorescent protein (Ab42(F19D)-
GFP); Green fluorescent protein (GFP); Protein A from Staphylococcus aureus and β-galactosidase 
(SpA β-gal); Isopropyl β-D-1-thiogalactopyranoside (IPTG); Not determined (N.D.); guanidinium 
chloride. (GnCl); CR: Congo red, Thioflavin-T (Th-T); S vs. IS: Soluble versus insoluble protein 
fractions; Inclusion bodies (IBs); Recombinant protein (RP). 
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